AI-Driven Tools Enhance CAR T-Cell Therapy Research, Patent Filing

A team of investigators engaged in chimeric antigen receptor (CAR) T-cell therapy research has explored how AI-driven tools can enhance efficiency and insight distillation in this research. Their work is featured within late-breaking research presented at the American Association for Cancer Research Annual Meeting 2025 in Chicago, Illinois.

The team searched the publicly available clinical literature on multiple myeloma (MM) CAR T-cell therapies using two AI-driven tools: BiblioEngine from 23Strands and Cool.AF from Neural Hinge. They used these tools to digest the vast information on therapies’ manufacturing processes, clinical trial designs, and their ultimate therapeutic applications. They also examined the therapies’ patents in the European Union, India, and the US Patent and Trademark Office.

The two tools helped the team quickly sift through and compare datasets, finding trends in the design of clinical trials for CAR T-cell therapies and how the therapies are being used in clinical practice. They identified factors that led to patent success for the therapies and mapped out the current collaboration connections among authors of the examined literature.

With these findings from the AI-based analysis, the team was able to pinpoint unmet needs in MM care and opportunities for patent filing. They found that the insights from the analysis can inform the structuring of clinical trials for MM CAR T-cell therapies and the filing of patents in a manner that is careful to avoid intellectual property conflicts. The analysis also included possibilities for new connections between published researchers to grow the network of collaborations and amplify current work in CAR T-cell therapy development.

Reference

AACR Annual Meeting 2025. Section #51. https://www.abstractsonline.com/pp8/#!/20273/presentation/9835